radiolabelling

R&D

The development experience with GLP-1 analogues offers critical insights for navigating ADME challenges in contemporary peptide programmes.

Oncology

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.